H-1337 is under development as a multi-kinase inhibitor that inhibits various protein kinases for glaucoma and ocular hypertension.
Animal studies and other tests have confirmed that this pipeline drug has the effect of lowering intraocular pressure.
We believe its strong effectiveness in lowering intraocular pressure is attributed to its new mechanism of action.

We are conducting our first in-house clinical development, and in 2018, we completed Phase I/IIa clinical trials in the U.S.
The trial results were positive, confirming efficacy of H-1337 on the primary efficacy endpoint and no adverse safety events.
After that, we started Phase IIb clinical trial in the U.S. in December 2022.

In addition, in efforts to expand indications for the drug, we have confirmed its effects on pulmonary hypertension in animal studies etc. We are hopeful of being able to create new possibilities for H-1337.

in U.S.
Clinical indication Glaucoma and ocular hypertension
Development process Phase IIb clinical trials (U.S.) started
Licensee Developed internally

Development Progress

  • 2022.12
    Phase IIb clinical trials (U.S.) started
  • 2018.09
    Phase I/IIa clinical trials (U.S.) completed
  • 2018.03
    Phase I/IIa clinical trials (U.S.) started
  • 2016.04
    Non-clinical studies started